logo
  •   Home
  • Applications
    • Indications
  • Business
  • EpiSwitch®
  • Products
    • EpiSwitch® Checkpoint Inhibitor Response Test
    • EpiSwitch® COVID-19 Severity Test
    • EpiSwitch® Explorer Array Kit
    • EPISWITCH® ANALYTICAL PORTAL
    • EpiSwitch® Service
  • Investors
    • Investors Overview
    • Results and Presentations
    • Share Price Information
    • Regulatory News
    • Board & Governance
    • Key Corporate Documents
    • AIM Rule 26
    • Email Alerts
    • Investor Contacts
  • News
  • About Us
    • History
    • Board of Directors
    • Management Team
    • Scientific Advisory Panel
    • Values
    • Careers
    • Contact Us
"A pilot study of chromosomal aberrations and epigenetic changes in peripheral blood samples to identify patients with melanoma".
  1. Home
  2. Publications
  3. OBD collaborative work with the Mayo Clinic on the successful validation of a melanoma EpiSwitch™ signature has been published in Melanoma Research.
  4. "A pilot study of chromosomal aberrations and epigenetic changes in peripheral blood samples to identify patients with melanoma".

"A pilot study of chromosomal aberrations and epigenetic changes in peripheral blood samples to identify patients with melanoma".

Terms of Use / Site Map / Privacy Policy / Cookies Policy

Regulated and Licensed by Human Tissue Authority
License No. 12571
© 2002-2021 Oxford Biodynamics Plc

Privacy Preference Center

Privacy Preferences